Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.22.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating Activities:    
Net loss $ (7,573) $ (7,999)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 3] 60 64
Stock-based compensation [note 7[c], note 7[d], note 7[e] and note 7[f]] 823 542
Shares issued as settlement with trade vendor 26 23
Accrued interest on SVB convertible debt [note 6] 271  
Changes in operating assets and liabilities:    
Grant receivable 153  
Prepaid expenses and other assets (10) 318
Accounts payable (423) 253
Accrued liabilities other 300 (373)
Accrued clinical liabilities 870 1,677
Accrued compensation (1,277) (952)
Lease obligation [note 8] 1 (5)
Net cash used in operating activities (6,779) (6,452)
Financing Activities:    
Proceeds from exercise of warrants 24 236
Proceeds from ATM, net of issuance costs 91  
Financing costs relating to convertible debt with SVB [note 6] (20)  
Net cash provided by financing activities 95 236
Effect of exchange rate changes on cash (1)  
Net decrease in cash, cash equivalents and restricted cash (6,685) (6,216)
Cash, cash equivalents and restricted cash at beginning of the period 43,072 35,903
Cash, cash equivalents and restricted cash at end of the period $ 36,387 $ 29,687